Related Experiment Videos
[Prognostic factors in non-Hodgkin's lymphoma in childhood]
Insights
Prognosis for pediatric Non-Hodgkin Lymphoma is significantly influenced by disease stage and histology. Good prognosis patients achieved 88% survival, while poor prognosis patients had 40% survival, highlighting the importance of these factors.
Area of Science:
- Pediatric Oncology
- Hematology
- Clinical Research
Context:
- Non-Hodgkin Lymphoma (NHL) is a significant pediatric malignancy.
- Treatment strategies and prognostic factors require continuous evaluation.
- This study retrospectively analyzed outcomes for children treated between 1974 and 1982.
Purpose:
- To evaluate the prognostic significance of clinical staging and histology in pediatric Non-Hodgkin Lymphoma.
- To compare treatment outcomes between distinct prognostic groups.
Summary:
- 38 children with Non-Hodgkin Lymphoma were stratified into Good Prognosis (completely resectable disease) and Poor Prognosis (mediastinal, bone marrow, CNS involvement, or diffuse/non-resectable disease) groups.
- Good Prognosis group achieved 100% complete remission and 88% 8.5-year survival.
- Poor Prognosis group had 83% complete remission but only 40% 8.5-year survival, with higher relapse rates (50%) and deaths (60%). Mediastinal involvement and Burkitt histology were associated with poorer outcomes.
Impact:
- The findings underscore the critical role of clinical staging and histological type (e.g., Burkitt Lymphoma) in determining prognosis for pediatric NHL.
- This supports tailored treatment approaches based on risk stratification.
- Long-term survival data provides valuable insights for historical treatment protocols.
Abstract:
38 children with Non-Hodgkin Lymphoma (age 15 months - 17 years; 27 males and 11 females) have been treated between 1974 and 1982. They have been divided in two different groups: a Good Prognosis group for patients with complete resectable disease and a Poor Prognosis group including patients with mediastinal, bone marrow or CNS involvement or with diffuse and non completely resectable localization. In the Good Prognosis group there were 100% Complete Remission, 12.5% Local Relapses and 12.5% deaths. 88% of patients are alive at 8 1/2 years follow-up. In the Poor Prognosis group there were 83% Complete Remission, 50% Relapses (8 in the first year, 2 in the second and 5 in the third and no more in the next years) and 60% Deaths; 30% of patients are off-therapy with a survival of 40% at 8 1/2 years follow-up. Among the 19 patients with mediastinal involvement there were 84.2% Complete Remission, 68.4% Relapses, 63.1% Deaths and 26.6% off therapy patients. Among the 19 patients with mediastinal involvement there were 84.2% Complete Remission, 68.4% Relapses, 63.1% Deaths and 26.6% off therapy patients. Survival is 70% for the group without mediastinal involvement and 35% for the group with mediastinal involvement. Burkitt-type Lymphoma has a survival of 30% in contrast to the 60% survival for all the others histological types. In summary we conclude that the distinction between Good Prognosis and Poor Prognosis groups, on the basis of a clinical stage involvement and Burkitt histology have an important role for prognosis of Non-Hodgkin Lymphoma in children.